StockMacro
Menu

Exelixis

$64.63 +29% in 6 monthsMarket cap $15.8B

EXEL on XNAS, Health Care, Exelixis Inc, job postings

Measures activity, not value. Not investment advice.

Net income rose 31% to $885.1M while short interest stands at 10% of shares.

  • GoodRevenue up 10% to $658.7M in the latest quarter

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 2 Oct 2026

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
1,077
Website
exelixis.com
Listed
Nasdaq, US
Last results
29 Oct 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 2 Oct 2026: revenue $658.7M, net income $218.1M.
Quarter to 31 Dec 2021: revenue $451.1M, net income $95.2MQuarter to 31 Dec 2021: revenue $451.1M, net income $95.2MQuarter to 1 Apr 2022: revenue $356.0M, net income $68.6MQuarter to 1 Apr 2022: revenue $356.0M, net income $68.6MQuarter to 1 Jul 2022: revenue $419.4M, net income $70.7MQuarter to 1 Jul 2022: revenue $419.4M, net income $70.7MQuarter to 30 Sep 2022: revenue $411.7M, net income $73.2MQuarter to 30 Sep 2022: revenue $411.7M, net income $73.2MQuarter to 30 Dec 2022: revenue $423.9M, net income -$30.2MQuarter to 30 Dec 2022: revenue $423.9M, net income -$30.2MQuarter to 31 Mar 2023: revenue $408.8M, net income $40.0MQuarter to 31 Mar 2023: revenue $408.8M, net income $40.0MQuarter to 30 Jun 2023: revenue $469.8M, net income $81.2MQuarter to 30 Jun 2023: revenue $469.8M, net income $81.2MQuarter to 29 Sep 2023: revenue $471.9M, net income $1.0MQuarter to 29 Sep 2023: revenue $471.9M, net income $1.0MQuarter to 29 Dec 2023: revenue $479.7M, net income $85.5MQuarter to 29 Dec 2023: revenue $479.7M, net income $85.5MQuarter to 29 Mar 2024: revenue $425.2M, net income $37.3MQuarter to 29 Mar 2024: revenue $425.2M, net income $37.3MQuarter to 28 Jun 2024: revenue $637.2M, net income $226.1MQuarter to 28 Jun 2024: revenue $637.2M, net income $226.1MQuarter to 27 Sep 2024: revenue $539.5M, net income $118.0MQuarter to 27 Sep 2024: revenue $539.5M, net income $118.0MQuarter to 3 Jan 2025: revenue $566.8M, net income $139.9MQuarter to 3 Jan 2025: revenue $566.8M, net income $139.9MQuarter to 4 Apr 2025: revenue $555.4M, net income $159.6MQuarter to 4 Apr 2025: revenue $555.4M, net income $159.6MQuarter to 4 Jul 2025: revenue $568.3M, net income $184.8MQuarter to 4 Jul 2025: revenue $568.3M, net income $184.8MQuarter to 3 Oct 2025: revenue $597.8M, net income $193.6MQuarter to 3 Oct 2025: revenue $597.8M, net income $193.6MQuarter to 2 Jan 2026: revenue $598.7M, net income $244.5MQuarter to 2 Jan 2026: revenue $598.7M, net income $244.5MQuarter to 3 Apr 2026: revenue $610.8M, net income $210.5MQuarter to 3 Apr 2026: revenue $610.8M, net income $210.5MQuarter to 3 Jul 2026: revenue $628.7M, net income $212.1MQuarter to 3 Jul 2026: revenue $628.7M, net income $212.1MQuarter to 2 Oct 2026: revenue $658.7M, net income $218.1MQuarter to 2 Oct 2026: revenue $658.7M, net income $218.1M
31 Dec 2021RevenueNet incomeNet losstallest bar $658.7M2 Oct 2026
See the numbers
Quarter toRevenueNet income
2 Oct 2026$658.7M$218.1M
3 Jul 2026$628.7M$212.1M
3 Apr 2026$610.8M$210.5M
2 Jan 2026$598.7M$244.5M
3 Oct 2025$597.8M$193.6M
4 Jul 2025$568.3M$184.8M
4 Apr 2025$555.4M$159.6M
3 Jan 2025$566.8M$139.9M
27 Sep 2024$539.5M$118.0M
28 Jun 2024$637.2M$226.1M
29 Mar 2024$425.2M$37.3M
29 Dec 2023$479.7M$85.5M
29 Sep 2023$471.9M$1.0M
30 Jun 2023$469.8M$81.2M
31 Mar 2023$408.8M$40.0M
30 Dec 2022$423.9M-$30.2M
30 Sep 2022$411.7M$73.2M
1 Jul 2022$419.4M$70.7M
1 Apr 2022$356.0M$68.6M
31 Dec 2021$451.1M$95.2M
Fundamentals, 12 months to 2 Oct 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $2.5B $2.3B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +9.1% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $885.1M $677.9M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $3.34 $2.37
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 96.3% 96.6% 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 40.2% 35.0% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 35.5% 29.6% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 44.3% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $1.2B $779.8M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $892.0M $988.5M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$892.0M (net cash) -$988.5M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $7.52
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 17.8 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 6.3 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 6.0 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 8.6 2.0

Latest = 12 months to 2 Oct 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
ExelixisEXEL (this company) $15.8B17.86.3+9.1%35.5%
Neurocrine BiosciencesNBIX $15.2B21.74.1+38%19.0%
Bio-TechneTECH $11.4B66.49.3+0.9%14.0%
RepligenRGEN $10.5Bloss13.0+14%-1.5%
Halozyme TherapeuticsHALO $10.4B21.55.8+45%26.9%
Kymera TherapeuticsKYMR $9.8Bloss96.3+134%-342%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+3.6%

767 13F filers vs 740

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

246.4M shares held by 13F filers (30 Sep 2026) of 244.0M outstanding (19 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

10%

25.6M shares sold short (30 Oct 2026) of 244.0M outstanding (19 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

11.7

25.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-6.3%

27.3M shares sold short in the report before, 25.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

69%

69% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 55%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-21%

31 vs 39 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+10%

$658.7M vs $597.8M (quarter ended 2 Oct 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+68%

$2.5M vs $1.5M (quarter ended 2 Oct 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$2.2M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

17

17 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

5.7×

17 articles in the last 7 days; its usual week has 3.

Price $64.63 on 20 Nov 2026, +55% over 12 months (12-month range $40.74 to $72.75)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $31.8M in the last 12 months (the 12 months before: -$43.7M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 31 published in the last 12 months, -21% on the 12 months before.
Revenue per quarter. Revenue $658.7M in the latest quarter, +10% on a year earlier.
Capital spending per quarter. Capital spending $2.5M in the latest quarter, +68% on a year earlier.
Institutional holders (13F filers). 767 13F filers reported holding it in the latest 13F quarter, +30% on a year earlier.
Lobbying spend. Lobbying spend: $2.2M published in the last 12 months, +14% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
29 May 20268-K and other filingsDirector or officer change
29 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 May 2026Lobbying filingnew lobbying registration (W STRATEGIES, LLC)
17 Apr 2026Lobbying filinglobbying engagement terminated (LMH STRATEGIC SOLUTIONS)
3 Mar 2026Sharp changeShort interest spike: short interest spike, 28.8M vs usual 18.7M (2026-02-13); 1.8x the same period a year earlier
17 Feb 2026Sharp changeShort interest spike: short interest spike, 27.9M vs usual 18.4M (2026-01-30); 2.1x the same period a year earlier
7 Nov 20258-K and other filingsDirector or officer change
21 Oct 2025Sharp changeLobbying on a new issue: lobbying on a new issue: PHA (2025-09-30)
29 Aug 20258-K and other filingsDirector or officer change
29 Aug 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Aug 2025Sharp changeMany funds opening a new position: many funds opening a new position, 107 vs usual 47 (2025-06-30); 2.9x the same period a year earlier
16 Jul 2025Lobbying filingnew lobbying registration (LMH STRATEGIC SOLUTIONS)
15 May 2025Sharp changeMany funds opening a new position: many funds opening a new position, 84 vs usual 43 (2025-03-31); 1.9x the same period a year earlier
13 May 2025Sharp changeShort interest spike: short interest spike, 19.2M vs usual 10.4M (2025-04-30); 2.0x the same period a year earlier
31 Mar 20258-K and other filingsDirector or officer change
31 Mar 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Mar 2025Sharp changeShort interest spike: short interest spike, 16.1M vs usual 9.8M (2025-02-14); 1.9x the same period a year earlier
18 Feb 2025Sharp changeMany funds opening a new position: many funds opening a new position, 87 vs usual 42 (2024-12-31); 1.7x the same period a year earlier
28 Jan 2025Sharp changeShort interest spike: short interest spike, 14.5M vs usual 9.2M (2025-01-15); 1.7x the same period a year earlier
19 Nov 2024Sharp changeMany funds opening a new position: many funds opening a new position, 70 vs usual 42 (2024-09-30); 1.7x the same period a year earlier
21 Oct 2024Sharp changeLobbying on a new issue: lobbying on a new issue: CPT (2024-09-30)
13 Aug 2024Sharp changeQuarterly revenue change: quarterly revenue change, 637.2M vs usual 424.6M (2024-06-28); 1.4x the same period a year earlier
3 Jun 20248-K and other filingsDirector or officer change
29 Mar 20248-K and other filingsDirector or officer change
19 Jan 2024Lobbying filinglobbying engagement terminated (ARNOLD & PORTER KAYE SCHOLER LLP)
8 Jan 20248-K and other filingsDirector or officer change
8 Jan 20248-K and other filingsRestructuring costs announced
20 Dec 20238-K and other filingsDirector or officer change
20 Dec 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
24 Oct 2023Sharp changeLobbying spend jump: lobbying spend jump, 460K vs usual 310K (2023-09-30); 1.4x the same period a year earlier
19 Sep 20238-K and other filingsDirector or officer change
23 Aug 20238-K and other filingsDirector or officer change
23 Aug 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Jul 2023Sharp changeLobbying spend jump: lobbying spend jump, 460K vs usual 295K (2023-06-30); 1.5x the same period a year earlier
18 Jul 2023Lobbying filingnew lobbying registration (TODD STRATEGY GROUP)
8 May 20238-K and other filingsDirector or officer change
13 Apr 20238-K and other filingsDirector or officer change
13 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Dec 20228-K and other filingsDirector or officer change
15 Dec 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Oct 2022Sharp changeLobbying spend jump: lobbying spend jump, 320K vs usual 235K (2022-09-30); 1.4x the same period a year earlier
20 Jul 2022Sharp changeLobbying on a new issue: lobbying on a new issue: TAX (2022-06-30)
27 May 20228-K and other filingsDirector or officer change
13 Apr 20228-K and other filingsDirector or officer change
13 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 Feb 2022Sharp changeQuarterly revenue change: quarterly revenue change, 451.1M vs usual 264.8M (2021-12-31); 1.7x the same period a year earlier
17 Dec 20218-K and other filingsDirector or officer change
17 Dec 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Nov 2021: -$650K published
Month from 1 Dec 2021: -$828K published
Month from 1 Feb 2022: -$3.1M published
Month from 1 Mar 2022: -$1.8M published
Month from 1 Apr 2022: -$608K published
Month from 1 May 2022: -$786K published
Month from 1 Jun 2022: -$343K published
Month from 1 Sep 2022: -$718K published
Month from 1 Nov 2022: -$818K published
Month from 1 Dec 2022: -$985K published
Month from 1 Feb 2023: -$1.8M published
Month from 1 Mar 2023: -$3.0M published
Month from 1 Apr 2023: -$779K published
Month from 1 Aug 2023: -$4.2M published
Month from 1 Sep 2023: -$103K published
Month from 1 Nov 2023: $0 published
Month from 1 Dec 2023: -$3.2M published
Month from 1 Feb 2024: $2.9M published
Month from 1 Mar 2024: -$461K published
Month from 1 May 2024: $7.4M published
Month from 1 Jun 2024: -$182K published
Month from 1 Aug 2024: -$10.4M published
Month from 1 Sep 2024: -$660K published
Month from 1 Oct 2024: -$710K published
Month from 1 Nov 2024: -$7.9M published
Month from 1 Dec 2024: -$2.2M published
Month from 1 Feb 2025: -$7.6M published
Month from 1 Mar 2025: -$3.5M published
Month from 1 May 2025: -$19.9M published
Month from 1 Jun 2025: -$1.1M published
Month from 1 Nov 2025: -$9.3M published
Month from 1 Feb 2026: -$20.6M published
Month from 1 May 2026: -$9.9M published
Month from 1 Jun 2026: -$690K published
Month from 1 Aug 2026: -$527K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 4 published
Quarter from 1 Apr 2022: 6 published
Quarter from 1 Jul 2022: 6 published
Quarter from 1 Oct 2022: 12 published
Quarter from 1 Jan 2023: 6 published
Quarter from 1 Apr 2023: 7 published
Quarter from 1 Jul 2023: 8 published
Quarter from 1 Oct 2023: 4 published
Quarter from 1 Jan 2024: 4 published
Quarter from 1 Apr 2024: 5 published
Quarter from 1 Jul 2024: 10 published
Quarter from 1 Oct 2024: 5 published
Quarter from 1 Jan 2025: 12 published
Quarter from 1 Apr 2025: 9 published
Quarter from 1 Jul 2025: 11 published
Quarter from 1 Oct 2025: 7 published
Quarter from 1 Jan 2026: 6 published
Quarter from 1 Apr 2026: 11 published
Quarter from 1 Jul 2026: 9 published
Quarter from 1 Oct 2026: 5 published
Revenue per quarter
Quarter ended 31 Dec 2021: $451.1M, +67% on a year earlier; public on 19 Feb 2022
Quarter ended 1 Apr 2022: $356.0M, +32% on a year earlier; public on 11 May 2022
Quarter ended 1 Jul 2022: $419.4M, +8.9% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $411.7M, +25% on a year earlier; public on 2 Nov 2022
Quarter ended 30 Dec 2022: $423.9M, -6.0% on a year earlier; public on 8 Feb 2023
Quarter ended 31 Mar 2023: $408.8M, +15% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $469.8M, +12% on a year earlier; public on 2 Aug 2023
Quarter ended 29 Sep 2023: $471.9M, +15% on a year earlier; public on 2 Nov 2023
Quarter ended 29 Dec 2023: $479.7M, +13% on a year earlier; public on 7 Feb 2024
Quarter ended 29 Mar 2024: $425.2M, +4.0% on a year earlier; public on 1 May 2024
Quarter ended 28 Jun 2024: $637.2M, +36% on a year earlier; public on 7 Aug 2024
Quarter ended 27 Sep 2024: $539.5M, +14% on a year earlier; public on 30 Oct 2024
Quarter ended 3 Jan 2025: $566.8M, +18% on a year earlier; public on 12 Feb 2025
Quarter ended 4 Apr 2025: $555.4M, +31% on a year earlier; public on 14 May 2025
Quarter ended 4 Jul 2025: $568.3M, -11% on a year earlier; public on 29 Jul 2025
Quarter ended 3 Oct 2025: $597.8M, +11% on a year earlier; public on 5 Nov 2025
Quarter ended 2 Jan 2026: $598.7M, +5.6% on a year earlier; public on 11 Feb 2026
Quarter ended 3 Apr 2026: $610.8M, +10% on a year earlier; public on 6 May 2026
Quarter ended 3 Jul 2026: $628.7M, +11% on a year earlier; public on 6 Aug 2026
Quarter ended 2 Oct 2026: $658.7M, +10% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $16.0M, +12% on a year earlier; public on 19 Feb 2022
Quarter ended 1 Apr 2022: $5.6M, -59% on a year earlier; public on 11 May 2022
Quarter ended 1 Jul 2022: $12.3M, -39% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $8.0M, -45% on a year earlier; public on 2 Nov 2022
Quarter ended 31 Mar 2023: $12.0M, +114% on a year earlier; public on 10 May 2023
Quarter ended 29 Mar 2024: $9.7M, -19% on a year earlier; public on 1 May 2024
Quarter ended 28 Jun 2024: $6.6M; public on 7 Aug 2024
Quarter ended 27 Sep 2024: $8.2M; public on 30 Oct 2024
Quarter ended 3 Jan 2025: $4.0M; public on 12 Feb 2025
Quarter ended 4 Apr 2025: $3.0M, -70% on a year earlier; public on 14 May 2025
Quarter ended 4 Jul 2025: $2.8M, -57% on a year earlier; public on 29 Jul 2025
Quarter ended 3 Oct 2025: $1.5M, -82% on a year earlier; public on 5 Nov 2025
Quarter ended 2 Jan 2026: $1.2M, -71% on a year earlier; public on 11 Feb 2026
Quarter ended 3 Apr 2026: $1.5M, -49% on a year earlier; public on 6 May 2026
Quarter ended 3 Jul 2026: $6.8M, +140% on a year earlier; public on 6 Aug 2026
Quarter ended 2 Oct 2026: $2.5M, +68% on a year earlier; public on 30 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 296; public on 14 Feb 2022
31 Mar 2022 report: 344; public on 16 May 2022
30 Jun 2022 report: 349; public on 15 Aug 2022
30 Sep 2022 report: 356; public on 14 Nov 2022
31 Dec 2022 report: 351; public on 14 Feb 2023
31 Mar 2023 report: 335; public on 15 May 2023
30 Jun 2023 report: 344; public on 14 Aug 2023
30 Sep 2023 report: 364; public on 14 Nov 2023
31 Dec 2023 report: 396; public on 14 Feb 2024
31 Mar 2024 report: 396; public on 15 May 2024
30 Jun 2024 report: 383; public on 14 Aug 2024
30 Sep 2024 report: 422; public on 14 Nov 2024
31 Dec 2024 report: 501; public on 14 Feb 2025
31 Mar 2025 report: 522; public on 15 May 2025
30 Jun 2025 report: 598; public on 14 Aug 2025
30 Sep 2025 report: 588; public on 14 Nov 2025
31 Dec 2025 report: 643; public on 17 Feb 2026
31 Mar 2026 report: 673; public on 15 May 2026
30 Jun 2026 report: 740; public on 14 Aug 2026
30 Sep 2026 report: 767; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $280K published
Quarter from 1 Apr 2022: $290K published
Quarter from 1 Jul 2022: $300K published
Quarter from 1 Oct 2022: $320K published
Quarter from 1 Jan 2023: $330K published
Quarter from 1 Apr 2023: $440K published
Quarter from 1 Jul 2023: $460K published
Quarter from 1 Oct 2023: $460K published
Quarter from 1 Jan 2024: $450K published
Quarter from 1 Apr 2024: $450K published
Quarter from 1 Jul 2024: $460K published
Quarter from 1 Oct 2024: $460K published
Quarter from 1 Jan 2025: $460K published
Quarter from 1 Apr 2025: $460K published
Quarter from 1 Jul 2025: $480K published
Quarter from 1 Oct 2025: $510K published
Quarter from 1 Jan 2026: $510K published
Quarter from 1 Apr 2026: $520K published
Quarter from 1 Jul 2026: $560K published
Quarter from 1 Oct 2026: $580K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is lobbying spend reported (quarter) at $580K (30 Sep 2026), 1.2× its normal reading; higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $31.8M in the last 12 months (the 12 months before: -$43.7M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 31 published in the last 12 months, -21% on the 12 months before.
  • Revenue per quarter: Revenue $658.7M in the latest quarter, +10% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

No trades in the last 90 days; the latest was filed 12 Aug 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
12 Aug 2026Mary C BeckerleDirectorSellplanned in advance (10b5-1)9,812$53.66$527KForm 4
3 Jun 2026Sue Gail EckhardtDirectorSellplanned in advance (10b5-1)9,812$50.14$492KForm 4
3 Jun 2026Jack L WyszomierskiDirectorSellplanned in advance (10b5-1)3,925$50.55$198KForm 4
28 May 2026Dana AftabEVP, Research and DevelopmentSell43,451$50.35$2.2MForm 4
22 May 2026Patrick J. HaleyEVP, CommercialSell32,110$49.81$1.6MForm 4
19 May 2026Christopher J. SennerEVP and CFOSell34,901$50.00$1.7MForm 4
19 May 2026Brenda HeftiSVP and General CounselSellplanned in advance (10b5-1)6,625$50.21$333KForm 4
8 May 2026Mary C BeckerleDirectorSellafter exercising options7,712$48.45$374KForm 4

767 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 89 opened a position, 68 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.29.7M12.2%$1.7B+668K+2.3%
Farallon Capital Management, L.L.C.14.7M6.02%$858.3M+1.2M+9.1%
Renaissance Technologies LLC12.8M5.24%$747.2M-635K-4.7%
Vanguard Portfolio Management LLC12.0M4.90%$698.3M-87K-0.7%
Vanguard Capital Management LLC10.8M4.41%$628.4M-192K-1.8%
State Street Corp10.5M4.31%$614.6M+551K+5.5%
AQR Capital Management LLC9.6M3.94%$561.2M-1.4M-13%
Fuller & Thaler Asset Management, Inc.8.8M3.60%$513.8M-133K-1.5%
Geode Capital Management, LLC8.2M3.38%$481.5M+592K+7.7%
LSV Asset Management7.9M3.23%-257K-3.2%

Company events

All 41 company events

In 12 months: 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
29 May 2026Director or officer changeSame filing: shareholder vote results8-K
7 Nov 2025Director or officer change8-K
29 Aug 2025Director or officer change8-K
31 Mar 2025Director or officer change8-K
3 Jun 2024Director or officer changeSame filing: shareholder vote results8-K
29 Mar 2024Director or officer change8-K
8 Jan 2024Director or officer change; Restructuring costs announced8-K
20 Dec 2023Director or officer changeSame filing: changed its bylaws or fiscal year8-K

Reported lobbying spend: $580K in Q3 2026, $560K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Apr 2026NewW Strategies, LLCfor Exelixis, Inc.Education about access to prescription drugs.PharmacyFiling
31 Dec 2025EndedLMH Strategic Solutionsfor Exelixis, Inc.Prescription drug payment reform. Pharmaceutical supply chain.; General Medicare and Medicaid Issues.Pharmacy, Medicare/MedicaidFiling
1 Jul 2025NewLMH Strategic Solutionsfor Exelixis, Inc.Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues.Pharmacy, Medicare/MedicaidFiling
31 Dec 2023EndedArnold & Porter Kaye Scholer LLPfor Exelixis, Inc.Not statedFiling
1 Apr 2023NewTodd Strategy Groupfor Exelixis, Inc.Policy to advance pharmaceutical research and development. 340B. Implementation of Inflation Reduction Act of 2022.Health issues, Medicare/MedicaidFiling
1 Jan 2020NewThorn Run Partnersfor ExelixisIssues related to pharmaceutical pricing.Health issuesFiling
1 May 2019EndedEast End Group, LLCfor Exelixis, Inc.Issues related to Medicare Part D program policy changes; and issues related to pricing of prescription drugs.Health issuesFiling
1 Mar 2019NewExelixis Inc.its own lobbyistsIssues relating to pharmaceutical pricingHealth issuesFiling
Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

15 May 2025confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Exelixis (EXEL): had 19.2M shares sold short in the 30 Apr 2025 report, 2.0× the same report last year, while it saw 84 13F filers open a new position in the quarter ended 31 Mar 2025, 1.9× the same quarter last year. Two unrelated kinds of activity within 2 days.

  • Short interest and volume: Short interest spike, became public on 10 May 2025
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2025
2024-04-30: 9.6M2024-05-15: 10.7M2024-05-31: 10.4M2024-06-14: 9.9M2024-06-28: 9.2M2024-07-15: 9.0M2024-07-31: 10.2M2024-08-15: 11.8M2024-08-30: 12.0M2024-09-13: 12.7M2024-09-30: 10.1M2024-10-15: 10.0M2024-10-31: 9.1M2024-11-15: 7.9M2024-11-29: 8.4M2024-12-13: 7.3M2024-12-31: 10.5M2025-01-15: 14.5M2025-01-31: 13.1M2025-02-14: 16.1M2025-02-28: 13.3M2025-03-14: 13.2M2025-03-31: 14.9M2025-04-15: 18.2M2025-04-30: 19.2M
The 30 Apr 2025 report against the 24 reports before it. this reportearliernormal: 10.4M
See the evidence (2 changes)

Short interest and volume: Short interest spike became public on 10 May 2025

Exelixis had 19.2M shares sold short in the 30 Apr 2025 report, 2.0× the same report last year.

This period
19.2M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
10.4M
Typical spread (median absolute deviation)
1.5M
How far from its usual level
+3.9
Same report last year
9.6M
History used
2,679 days
2024-04-30: 9.6M2024-05-15: 10.7M2024-05-31: 10.4M2024-06-14: 9.9M2024-06-28: 9.2M2024-07-15: 9.0M2024-07-31: 10.2M2024-08-15: 11.8M2024-08-30: 12.0M2024-09-13: 12.7M2024-09-30: 10.1M2024-10-15: 10.0M2024-10-31: 9.1M2024-11-15: 7.9M2024-11-29: 8.4M2024-12-13: 7.3M2024-12-31: 10.5M2025-01-15: 14.5M2025-01-31: 13.1M2025-02-14: 16.1M2025-02-28: 13.3M2025-03-14: 13.2M2025-03-31: 14.9M2025-04-15: 18.2M2025-04-30: 19.2M
the 30 Apr 2025 report24 earlier reportsnormal: 10.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 15 May 2025

Exelixis saw 84 13F filers open a new position in the quarter ended 31 Mar 2025, 1.9× the same quarter last year.

This period
84 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
43
Typical spread (median absolute deviation)
6.5
How far from its usual level
+4.3
Same quarter last year
44
History used
4,200 days
2023-03-31: 302023-06-30: 422023-09-30: 422023-12-31: 502024-03-31: 442024-06-30: 372024-09-30: 702024-12-31: 872025-03-31: 84
the quarter ended 31 Mar 20258 earlier quartersnormal: 43

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

18 Feb 2025confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Exelixis (EXEL): saw 87 13F filers open a new position in the quarter ended 31 Dec 2024, 1.7× the same quarter last year, while it had 16.1M shares sold short in the 14 Feb 2025 report, 1.9× the same report last year. Two unrelated kinds of activity within 35 days.

  • Short interest and volume: Short interest spike, became public on 28 Jan 2025
  • Institutional holdings: Many funds opening a new position, became public on 14 Feb 2025
  • Short interest and volume: Short interest spike, became public on 27 Feb 2025
2022-12-31: 372023-03-31: 302023-06-30: 422023-09-30: 422023-12-31: 502024-03-31: 442024-06-30: 372024-09-30: 702024-12-31: 87
The quarter ended 31 Dec 2024 against the 8 quarters before it. this quarterearliernormal: 42
See the evidence (3 changes)

Short interest and volume: Short interest spike became public on 28 Jan 2025

Exelixis had 14.5M shares sold short in the 15 Jan 2025 report, 1.7× the same report last year.

This period
14.5M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
9.2M
Typical spread (median absolute deviation)
900K
How far from its usual level
+4.0
Same report last year
8.6M
History used
2,574 days
2024-01-12: 8.6M2024-01-31: 7.3M2024-02-15: 8.4M2024-02-29: 8.9M2024-03-15: 8.3M2024-03-28: 6.8M2024-04-15: 8.6M2024-04-30: 9.6M2024-05-15: 10.7M2024-05-31: 10.4M2024-06-14: 9.9M2024-06-28: 9.2M2024-07-15: 9.0M2024-07-31: 10.2M2024-08-15: 11.8M2024-08-30: 12.0M2024-09-13: 12.7M2024-09-30: 10.1M2024-10-15: 10.0M2024-10-31: 9.1M2024-11-15: 7.9M2024-11-29: 8.4M2024-12-13: 7.3M2024-12-31: 10.5M2025-01-15: 14.5M
the 15 Jan 2025 report24 earlier reportsnormal: 9.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 14 Feb 2025

Exelixis saw 87 13F filers open a new position in the quarter ended 31 Dec 2024, 1.7× the same quarter last year.

This period
87 (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
42
Typical spread (median absolute deviation)
5
How far from its usual level
+6.1
Same quarter last year
50
History used
4,110 days
2022-12-31: 372023-03-31: 302023-06-30: 422023-09-30: 422023-12-31: 502024-03-31: 442024-06-30: 372024-09-30: 702024-12-31: 87
the quarter ended 31 Dec 20248 earlier quartersnormal: 42

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 27 Feb 2025

Exelixis had 16.1M shares sold short in the 14 Feb 2025 report, 1.9× the same report last year.

This period
16.1M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
1.0M
How far from its usual level
+4.1
Same report last year
8.4M
History used
2,604 days
2024-02-15: 8.4M2024-02-29: 8.9M2024-03-15: 8.3M2024-03-28: 6.8M2024-04-15: 8.6M2024-04-30: 9.6M2024-05-15: 10.7M2024-05-31: 10.4M2024-06-14: 9.9M2024-06-28: 9.2M2024-07-15: 9.0M2024-07-31: 10.2M2024-08-15: 11.8M2024-08-30: 12.0M2024-09-13: 12.7M2024-09-30: 10.1M2024-10-15: 10.0M2024-10-31: 9.1M2024-11-15: 7.9M2024-11-29: 8.4M2024-12-13: 7.3M2024-12-31: 10.5M2025-01-15: 14.5M2025-01-31: 13.1M2025-02-14: 16.1M
the 14 Feb 2025 report24 earlier reportsnormal: 9.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

19 Nov 2024confirmed

Confirmed across sources Institutional holdings and Lobbying

Exelixis (EXEL): lobbying on a new issue, while it saw 70 13F filers open a new position in the quarter ended 30 Sep 2024, 1.7× the same quarter last year. Two unrelated kinds of activity within 29 days.

  • Lobbying: Lobbying on a new issue, became public on 21 Oct 2024
  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2024
2022-09-30: 582022-12-31: 372023-03-31: 302023-06-30: 422023-09-30: 422023-12-31: 502024-03-31: 442024-06-30: 372024-09-30: 70
The quarter ended 30 Sep 2024 against the 8 quarters before it. this quarterearliernormal: 42
See the evidence (2 changes)

Lobbying: Lobbying on a new issue became public on 21 Oct 2024

Exelixis lobbying on a new issue.

New
['CPT']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6275471

Institutional holdings: Many funds opening a new position became public on 14 Nov 2024

Exelixis saw 70 13F filers open a new position in the quarter ended 30 Sep 2024, 1.7× the same quarter last year.

This period
70 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
42
Typical spread (median absolute deviation)
5
How far from its usual level
+3.8
Same quarter last year
42
History used
4,018 days
2022-09-30: 582022-12-31: 372023-03-31: 302023-06-30: 422023-09-30: 422023-12-31: 502024-03-31: 442024-06-30: 372024-09-30: 70
the quarter ended 30 Sep 20248 earlier quartersnormal: 42

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 29 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 29 May 2026Filings record

    Director or officer change

  3. 7 May 2026Lobbying record

    EXELIXIS, INC.: new lobbying registration (W STRATEGIES, LLC) (dated 1 Apr 2026)

  4. 17 Apr 2026Lobbying record

    EXELIXIS, INC.: lobbying engagement terminated (LMH STRATEGIC SOLUTIONS) (dated 31 Dec 2025)

  5. 26 Feb 2026Short interest and volume change

    had 28.8M shares sold short in the 13 Feb 2026 report, 1.8× the same report last year.

    Same report last year: 16.1M; its normal report is 18.7M.

    See the evidence
    This period
    28.8M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    18.7M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +4.3
    Same report last year
    16.1M
    History used
    2,968 days
    2025-02-14: 16.1M2025-02-28: 13.3M2025-03-14: 13.2M2025-03-31: 14.9M2025-04-15: 18.2M2025-04-30: 19.2M2025-05-15: 18.7M2025-05-30: 18.6M2025-06-13: 20.4M2025-06-30: 19.4M2025-07-15: 18.3M2025-07-31: 17.4M2025-08-15: 16.9M2025-08-29: 17.6M2025-09-15: 17.6M2025-09-30: 17.7M2025-10-15: 20.9M2025-10-31: 19.8M2025-11-14: 20.1M2025-11-28: 21.4M2025-12-15: 22.8M2025-12-31: 24.7M2026-01-15: 25.8M2026-01-30: 27.9M2026-02-13: 28.8M
    the 13 Feb 2026 report24 earlier reportsnormal: 18.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 11 Feb 2026Short interest and volume change

    had 27.9M shares sold short in the 30 Jan 2026 report, 2.1× the same report last year.

    Same report last year: 13.1M; its normal report is 18.4M.

    See the evidence
    This period
    27.9M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    18.4M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +3.9
    Same report last year
    13.1M
    History used
    2,954 days
    2025-01-31: 13.1M2025-02-14: 16.1M2025-02-28: 13.3M2025-03-14: 13.2M2025-03-31: 14.9M2025-04-15: 18.2M2025-04-30: 19.2M2025-05-15: 18.7M2025-05-30: 18.6M2025-06-13: 20.4M2025-06-30: 19.4M2025-07-15: 18.3M2025-07-31: 17.4M2025-08-15: 16.9M2025-08-29: 17.6M2025-09-15: 17.6M2025-09-30: 17.7M2025-10-15: 20.9M2025-10-31: 19.8M2025-11-14: 20.1M2025-11-28: 21.4M2025-12-15: 22.8M2025-12-31: 24.7M2026-01-15: 25.8M2026-01-30: 27.9M
    the 30 Jan 2026 report24 earlier reportsnormal: 18.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 27 Nov 2025Insiders record

    Caligan Partners LP (See Remarks) and 1 other(s) bought 27,532 shares of EXEL ($1.2M) (dated 26 Nov 2025)

  8. 7 Nov 2025Filings record

    Director or officer change

  9. 21 Oct 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['PHA']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4690688
  10. 29 Aug 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 29 Aug 2025Filings record

    Director or officer change

  12. 14 Aug 2025Institutional holdings change

    saw 107 13F filers open a new position in the quarter ended 30 Jun 2025, 2.9× the same quarter last year.

    Same quarter last year: 37; its normal quarter is 47.

    See the evidence
    This period
    107 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    47
    Typical spread (median absolute deviation)
    7.5
    How far from its usual level
    +5.4
    Same quarter last year
    37
    History used
    4,291 days
    2023-06-30: 422023-09-30: 422023-12-31: 502024-03-31: 442024-06-30: 372024-09-30: 702024-12-31: 872025-03-31: 842025-06-30: 107
    the quarter ended 30 Jun 20258 earlier quartersnormal: 47

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  13. 16 Jul 2025Lobbying record

    EXELIXIS, INC.: new lobbying registration (LMH STRATEGIC SOLUTIONS) (dated 1 Jul 2025)

  14. 15 May 2025several at once

    had 19.2M shares sold short in the 30 Apr 2025 report, 2.0× the same report last year, while it saw 84 13F filers open a new position in the quarter ended 31 Mar 2025, 1.9× the same quarter last year. Two unrelated kinds of activity within 2 days.

    See the evidence (2 changes)

    Short interest and volume: Short interest spike became public on 10 May 2025

    Exelixis had 19.2M shares sold short in the 30 Apr 2025 report, 2.0× the same report last year.

    This period
    19.2M (the 30 Apr 2025 report)
    Normal report (median of 24 earlier)
    10.4M
    Typical spread (median absolute deviation)
    1.5M
    How far from its usual level
    +3.9
    Same report last year
    9.6M
    History used
    2,679 days
    2024-04-30: 9.6M2024-05-15: 10.7M2024-05-31: 10.4M2024-06-14: 9.9M2024-06-28: 9.2M2024-07-15: 9.0M2024-07-31: 10.2M2024-08-15: 11.8M2024-08-30: 12.0M2024-09-13: 12.7M2024-09-30: 10.1M2024-10-15: 10.0M2024-10-31: 9.1M2024-11-15: 7.9M2024-11-29: 8.4M2024-12-13: 7.3M2024-12-31: 10.5M2025-01-15: 14.5M2025-01-31: 13.1M2025-02-14: 16.1M2025-02-28: 13.3M2025-03-14: 13.2M2025-03-31: 14.9M2025-04-15: 18.2M2025-04-30: 19.2M
    the 30 Apr 2025 report24 earlier reportsnormal: 10.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 15 May 2025

    Exelixis saw 84 13F filers open a new position in the quarter ended 31 Mar 2025, 1.9× the same quarter last year.

    This period
    84 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    43
    Typical spread (median absolute deviation)
    6.5
    How far from its usual level
    +4.3
    Same quarter last year
    44
    History used
    4,200 days
    2023-03-31: 302023-06-30: 422023-09-30: 422023-12-31: 502024-03-31: 442024-06-30: 372024-09-30: 702024-12-31: 872025-03-31: 84
    the quarter ended 31 Mar 20258 earlier quartersnormal: 43

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  15. 15 May 2025Institutional holdings change

    saw 84 13F filers open a new position in the quarter ended 31 Mar 2025, 1.9× the same quarter last year.

    Same quarter last year: 44; its normal quarter is 43.

    See the evidence
    This period
    84 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    43
    Typical spread (median absolute deviation)
    6.5
    How far from its usual level
    +4.3
    Same quarter last year
    44
    History used
    4,200 days
    2023-03-31: 302023-06-30: 422023-09-30: 422023-12-31: 502024-03-31: 442024-06-30: 372024-09-30: 702024-12-31: 872025-03-31: 84
    the quarter ended 31 Mar 20258 earlier quartersnormal: 43

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  16. 10 May 2025Short interest and volume change

    had 19.2M shares sold short in the 30 Apr 2025 report, 2.0× the same report last year.

    Same report last year: 9.6M; its normal report is 10.4M.

    See the evidence
    This period
    19.2M (the 30 Apr 2025 report)
    Normal report (median of 24 earlier)
    10.4M
    Typical spread (median absolute deviation)
    1.5M
    How far from its usual level
    +3.9
    Same report last year
    9.6M
    History used
    2,679 days
    2024-04-30: 9.6M2024-05-15: 10.7M2024-05-31: 10.4M2024-06-14: 9.9M2024-06-28: 9.2M2024-07-15: 9.0M2024-07-31: 10.2M2024-08-15: 11.8M2024-08-30: 12.0M2024-09-13: 12.7M2024-09-30: 10.1M2024-10-15: 10.0M2024-10-31: 9.1M2024-11-15: 7.9M2024-11-29: 8.4M2024-12-13: 7.3M2024-12-31: 10.5M2025-01-15: 14.5M2025-01-31: 13.1M2025-02-14: 16.1M2025-02-28: 13.3M2025-03-14: 13.2M2025-03-31: 14.9M2025-04-15: 18.2M2025-04-30: 19.2M
    the 30 Apr 2025 report24 earlier reportsnormal: 10.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 31 Mar 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 31 Mar 2025Filings record

    Director or officer change

  19. 27 Feb 2025Short interest and volume change

    had 16.1M shares sold short in the 14 Feb 2025 report, 1.9× the same report last year.

    Same report last year: 8.4M; its normal report is 9.8M.

    See the evidence
    This period
    16.1M (the 14 Feb 2025 report)
    Normal report (median of 24 earlier)
    9.8M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +4.1
    Same report last year
    8.4M
    History used
    2,604 days
    2024-02-15: 8.4M2024-02-29: 8.9M2024-03-15: 8.3M2024-03-28: 6.8M2024-04-15: 8.6M2024-04-30: 9.6M2024-05-15: 10.7M2024-05-31: 10.4M2024-06-14: 9.9M2024-06-28: 9.2M2024-07-15: 9.0M2024-07-31: 10.2M2024-08-15: 11.8M2024-08-30: 12.0M2024-09-13: 12.7M2024-09-30: 10.1M2024-10-15: 10.0M2024-10-31: 9.1M2024-11-15: 7.9M2024-11-29: 8.4M2024-12-13: 7.3M2024-12-31: 10.5M2025-01-15: 14.5M2025-01-31: 13.1M2025-02-14: 16.1M
    the 14 Feb 2025 report24 earlier reportsnormal: 9.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 18 Feb 2025several at once

    saw 87 13F filers open a new position in the quarter ended 31 Dec 2024, 1.7× the same quarter last year, while it had 16.1M shares sold short in the 14 Feb 2025 report, 1.9× the same report last year. Two unrelated kinds of activity within 35 days.

    See the evidence (3 changes)

    Short interest and volume: Short interest spike became public on 28 Jan 2025

    Exelixis had 14.5M shares sold short in the 15 Jan 2025 report, 1.7× the same report last year.

    This period
    14.5M (the 15 Jan 2025 report)
    Normal report (median of 24 earlier)
    9.2M
    Typical spread (median absolute deviation)
    900K
    How far from its usual level
    +4.0
    Same report last year
    8.6M
    History used
    2,574 days
    2024-01-12: 8.6M2024-01-31: 7.3M2024-02-15: 8.4M2024-02-29: 8.9M2024-03-15: 8.3M2024-03-28: 6.8M2024-04-15: 8.6M2024-04-30: 9.6M2024-05-15: 10.7M2024-05-31: 10.4M2024-06-14: 9.9M2024-06-28: 9.2M2024-07-15: 9.0M2024-07-31: 10.2M2024-08-15: 11.8M2024-08-30: 12.0M2024-09-13: 12.7M2024-09-30: 10.1M2024-10-15: 10.0M2024-10-31: 9.1M2024-11-15: 7.9M2024-11-29: 8.4M2024-12-13: 7.3M2024-12-31: 10.5M2025-01-15: 14.5M
    the 15 Jan 2025 report24 earlier reportsnormal: 9.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 14 Feb 2025

    Exelixis saw 87 13F filers open a new position in the quarter ended 31 Dec 2024, 1.7× the same quarter last year.

    This period
    87 (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    42
    Typical spread (median absolute deviation)
    5
    How far from its usual level
    +6.1
    Same quarter last year
    50
    History used
    4,110 days
    2022-12-31: 372023-03-31: 302023-06-30: 422023-09-30: 422023-12-31: 502024-03-31: 442024-06-30: 372024-09-30: 702024-12-31: 87
    the quarter ended 31 Dec 20248 earlier quartersnormal: 42

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 27 Feb 2025

    Exelixis had 16.1M shares sold short in the 14 Feb 2025 report, 1.9× the same report last year.

    This period
    16.1M (the 14 Feb 2025 report)
    Normal report (median of 24 earlier)
    9.8M
    Typical spread (median absolute deviation)
    1.0M
    How far from its usual level
    +4.1
    Same report last year
    8.4M
    History used
    2,604 days
    2024-02-15: 8.4M2024-02-29: 8.9M2024-03-15: 8.3M2024-03-28: 6.8M2024-04-15: 8.6M2024-04-30: 9.6M2024-05-15: 10.7M2024-05-31: 10.4M2024-06-14: 9.9M2024-06-28: 9.2M2024-07-15: 9.0M2024-07-31: 10.2M2024-08-15: 11.8M2024-08-30: 12.0M2024-09-13: 12.7M2024-09-30: 10.1M2024-10-15: 10.0M2024-10-31: 9.1M2024-11-15: 7.9M2024-11-29: 8.4M2024-12-13: 7.3M2024-12-31: 10.5M2025-01-15: 14.5M2025-01-31: 13.1M2025-02-14: 16.1M
    the 14 Feb 2025 report24 earlier reportsnormal: 9.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  21. 14 Feb 2025Institutional holdings change

    saw 87 13F filers open a new position in the quarter ended 31 Dec 2024, 1.7× the same quarter last year.

    Same quarter last year: 50; its normal quarter is 42.

    See the evidence
    This period
    87 (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    42
    Typical spread (median absolute deviation)
    5
    How far from its usual level
    +6.1
    Same quarter last year
    50
    History used
    4,110 days
    2022-12-31: 372023-03-31: 302023-06-30: 422023-09-30: 422023-12-31: 502024-03-31: 442024-06-30: 372024-09-30: 702024-12-31: 87
    the quarter ended 31 Dec 20248 earlier quartersnormal: 42

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  22. 28 Jan 2025Short interest and volume change

    had 14.5M shares sold short in the 15 Jan 2025 report, 1.7× the same report last year.

    Same report last year: 8.6M; its normal report is 9.2M.

    See the evidence
    This period
    14.5M (the 15 Jan 2025 report)
    Normal report (median of 24 earlier)
    9.2M
    Typical spread (median absolute deviation)
    900K
    How far from its usual level
    +4.0
    Same report last year
    8.6M
    History used
    2,574 days
    2024-01-12: 8.6M2024-01-31: 7.3M2024-02-15: 8.4M2024-02-29: 8.9M2024-03-15: 8.3M2024-03-28: 6.8M2024-04-15: 8.6M2024-04-30: 9.6M2024-05-15: 10.7M2024-05-31: 10.4M2024-06-14: 9.9M2024-06-28: 9.2M2024-07-15: 9.0M2024-07-31: 10.2M2024-08-15: 11.8M2024-08-30: 12.0M2024-09-13: 12.7M2024-09-30: 10.1M2024-10-15: 10.0M2024-10-31: 9.1M2024-11-15: 7.9M2024-11-29: 8.4M2024-12-13: 7.3M2024-12-31: 10.5M2025-01-15: 14.5M
    the 15 Jan 2025 report24 earlier reportsnormal: 9.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 19 Nov 2024several at once

    lobbying on a new issue, while it saw 70 13F filers open a new position in the quarter ended 30 Sep 2024, 1.7× the same quarter last year. Two unrelated kinds of activity within 29 days.

    See the evidence (2 changes)

    Lobbying: Lobbying on a new issue became public on 21 Oct 2024

    Exelixis lobbying on a new issue.

    New
    ['CPT']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6275471

    Institutional holdings: Many funds opening a new position became public on 14 Nov 2024

    Exelixis saw 70 13F filers open a new position in the quarter ended 30 Sep 2024, 1.7× the same quarter last year.

    This period
    70 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    42
    Typical spread (median absolute deviation)
    5
    How far from its usual level
    +3.8
    Same quarter last year
    42
    History used
    4,018 days
    2022-09-30: 582022-12-31: 372023-03-31: 302023-06-30: 422023-09-30: 422023-12-31: 502024-03-31: 442024-06-30: 372024-09-30: 70
    the quarter ended 30 Sep 20248 earlier quartersnormal: 42

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  24. 14 Nov 2024Institutional holdings change

    saw 70 13F filers open a new position in the quarter ended 30 Sep 2024, 1.7× the same quarter last year.

    Same quarter last year: 42; its normal quarter is 42.

    See the evidence
    This period
    70 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    42
    Typical spread (median absolute deviation)
    5
    How far from its usual level
    +3.8
    Same quarter last year
    42
    History used
    4,018 days
    2022-09-30: 582022-12-31: 372023-03-31: 302023-06-30: 422023-09-30: 422023-12-31: 502024-03-31: 442024-06-30: 372024-09-30: 70
    the quarter ended 30 Sep 20248 earlier quartersnormal: 42

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  25. 21 Oct 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['CPT']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6275471
  26. 13 Aug 2024Financials change

    reported revenue of $637.2M for the quarter ended 28 Jun 2024, 1.4× the same quarter last year.

    Same quarter last year: $469.8M; its normal quarter is $424.6M.

    See the evidence
    This period
    $637.2M (the quarter ended 28 Jun 2024)
    Normal quarter (median of 8 earlier)
    $424.6M
    Typical spread (median absolute deviation)
    $14.3M
    How far from its usual level
    +5.0
    Same quarter last year
    $469.8M
    History used
    5,203 days
    2022-07-01: $419.4M2022-09-30: $411.7M2022-12-30: $423.9M2023-03-31: $408.8M2023-06-30: $469.8M2023-09-29: $471.9M2023-12-29: $479.7M2024-03-29: $425.2M2024-06-28: $637.2M
    the quarter ended 28 Jun 20248 earlier quartersnormal: $424.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  27. 3 Jun 2024Filings record

    Director or officer change

  28. 31 May 2024Insiders record

    JOHNSON DAVID EDWARD (director) and 1 other(s) bought 425,000 shares of EXEL ($8.7M) (dated 30 May 2024)

  29. 29 Mar 2024Filings record

    Director or officer change

  30. 23 Feb 2024Insiders record

    Caligan Partners LP (See Remarks) and 1 other(s) bought 190,000 shares of EXEL ($3.9M) (dated 22 Feb 2024)

  31. 19 Jan 2024Lobbying record

    EXELIXIS, INC.: lobbying engagement terminated (ARNOLD & PORTER KAYE SCHOLER LLP) (dated 31 Dec 2023)

  32. 8 Jan 2024Filings record

    Director or officer change

  33. 8 Jan 2024Filings record

    Restructuring costs announced

  34. 20 Dec 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 20 Dec 2023Filings record

    Director or officer change

  36. 30 Nov 2023Insiders record

    Caligan Partners LP (director) and 1 other(s) bought 120,409 shares of EXEL ($2.6M) (dated 29 Nov 2023)

  37. 21 Oct 2023Lobbying change

    reported $460K of lobbying spend for the quarter ended 30 Sep 2023, 1.4× the same quarter last year.

    Same quarter last year: $320K; its normal quarter is $310K.

    See the evidence
    This period
    $460K (the quarter ended 30 Sep 2023)
    Normal quarter (median of 8 earlier)
    $310K
    Typical spread (median absolute deviation)
    $25K
    How far from its usual level
    +4.0
    Same quarter last year
    $320K
    History used
    2,009 days
    2021-09-30: $230K2021-12-31: $280K2022-03-31: $290K2022-06-30: $300K2022-09-30: $320K2022-12-31: $330K2023-03-31: $440K2023-06-30: $460K2023-09-30: $460K
    the quarter ended 30 Sep 20238 earlier quartersnormal: $310K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  38. 19 Sep 2023Filings record

    Director or officer change

  39. 23 Aug 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 23 Aug 2023Filings record

    Director or officer change

Showing the newest 40 of 85 entries; narrow the window or the kind of data to see older ones.

Not listed: 475 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000939767
Ticker
EXEL
Domain
exelixis.com
Employer name
EXELIXIS, INC., Exelixis U.S. LLC (2 unverified)
Hq location
CA|ALAMEDA|94502 (1 unverified)
Lobbying client
exelixis
Name
Exelixis Inc, Exelixis Patent Company LLC, Exelixis Plant Sciences, Inc, Exelixis U.S., LLC
Uei
F2N1DL19LRX7, R47FPKTS9T63
Wikidata
Q5419989
Wikipedia
Exelixis
  • DOL H-1B labor condition applications and PERM certifications714 data points25 Nov 2019 to 24 Aug 2026
  • Federal lobbying disclosures (LDA)10 records, 105 data points15 Jan 2018 to 30 Sep 2026
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)163 records16 Feb 2016 to 29 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1293 data points31 Dec 2008 to 19 Oct 2026
  • SEC Form 4 insider transactions349 records, 932 data points11 May 2016 to 12 Aug 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards141 data points19 Dec 2013 to 27 Sep 2017
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026